Thu, Jul 31, 2014, 4:04 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Isis Pharmaceuticals, Inc. Message Board

riv1912 2 posts  |  Last Activity: May 1, 2014 9:35 AM Member since: Apr 1, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Antisense technology

    by riv1912 May 1, 2014 8:54 AM
    riv1912 riv1912 May 1, 2014 9:35 AM Flag

    Get some brain, it is better to put money on horse racing, in which you are guarantied that one horse will win. In drug development by small biotech companies, all runners may fail.

  • Many posts attribute the failure of Custirsen to the failure of antisense technology. However due to the very high failure rate in drug development cancer treatments, the later is more likely to be the reason of the failure.
    In addition, unlike many messages statements, there is an FDA approved antisense based drug: KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
    Hence one should not panic and throw away the entire technology of antisense based drugs.
    disclosure: own 300 shares of ISIS.

ISIS
30.99-0.89(-2.79%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.